Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jun 6;14:4145–4155. doi: 10.2147/IJN.S202466

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Pei et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Fullerol could reduce TNF-α, IL-1β, IL-6 and iNOS expression and nitrite production in primary mouse peritoneal macrophages.

Notes: Fullerol was not toxic at doses of up to 3 µM (A, WST-1 assay). Fullerol suppressed LPS-induced nitrite production (B, Griess reagent test) and iNOS gene expression (C, quantitative RT-PCR analysis). It also reversed LPS-stimulated production of TNF-α (D, ELISA assay; E, quantitative RT-PCR analysis) and expression of inflammatory cytokines IL-1β and IL-6 (F, quantitative RT-PCR analysis). LPS: LPS (100 ng/mL) treatment; LPS + FUL: treatment of LPS (100 ng/mL) combined with fullerol (1 µM).

Abbreviations: FUL, fullerol; NT, no treatment; iNOS, induced nitric oxide synthase; LPS, lipopolysaccharide; TNF, tumor necrosis factor.